ICYMI: New online! Identifying MASLD patient eligibility for pharmacological therapy: the need to integrate evidence into clinical practice
Nature Reviews Gastroenterology & Hepatology, Published online: 20 May 2026; doi:10.1038/s41575-026-01214-8Metabolic dysfunction-associated steatotic liver disease is a leading cause of chronic liver disease, with rising liver transplantation rates. New therapies such as resmetirom and semaglutide mark a shift in treatment. However, identifying suitable patients remains challenging, requiring integrated approaches combining fibrosis stage, metabolic factors and non-invasive tools in real-world practice.
